VistaGen Therapeutics(US:VTGN) TMX Newsfile·2026-01-24 12:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Trial Results and Stock Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock decline of $3.50 or 80.27%, closing at $0.86 [6]. - The study failed to show statistically significant improvement in anxiety reduction compared to placebo, raising concerns about the company's disclosures [5][6]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [8].